 we report on our second quarter 2020 financial results and discuss our plans for the second half of the year. 
 we also provide an update on the status of the ongoing clinical program for cytisinicline, including the exciting top line results from the first direct head-to-head comparative study between cytisinicline and the current market leader, Chantix. 
 we also discuss the status of the upcoming phase 3 trial for cytisinicline, the ORCA-2, 750-subject, placebo-controlled trial, which will start in the fourth quarter of this year.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 